Introduction
============

In 2012, colorectal cancer was estimated to be the third most common type of cancer after lung and prostate cancer in men, and the second most common after breast cancer in women worldwide. In terms of the mortality rate, it ranked fourth, after cancer of the lungs, liver and stomach in both men and women ([@b1-ijmm-37-02-0319]). Although colorectal cancer is principally treated by surgery, chemotherapy and radiotherapy may be given priority, depending on the stage of the disease. For many years, 5-fluo-rouracil (5-FU) alone or 5-FU and leucovorin were effectively used as chemotherapeutic agents for the treatment of colorectal cancer. However, the survival benefit in patients with metastatic colorectal cancer has been reported to be markedly increased by the combined use of chemotherapeutic agents, such as irinotecan and oxaliplatin with biological agents, such as bevacizumab for anti-vascular endothelial growth factor (VEGF) antibody therapy and cetuximab for anti-epidermal growth factor receptor (EGFR) antibody therapy, in addition to cytotoxic agents ([@b2-ijmm-37-02-0319]).

To increase the effectiveness of chemotherapy for patients with colorectal cancer, it is necessary to establish individualized treatment strategies and, therefore, identifying factors associated with the effects of chemotherapy for colorectal cancer also becomes important. Thymidylate synthase (TYMS), a 5-FU target, requires 5,10-methylenetetrahydrofolate (5,10-methylene-THF), a folate co-factor, as a methyl group donor and methylates deoxyuridine monophosphate (dUMP) to become deoxythymidine monophosphate (dTMP). It acts as a rate-limiting enzyme during DNA synthesis ([@b3-ijmm-37-02-0319]). As an active metabolite of 5-FU, 5-fluoro-dUMP (FdUMP) covalently links with TYMS and 5,10-methylene-THF, forming a ternary complex and inhibiting the TYMS response ([@b3-ijmm-37-02-0319]). Dihydropyrimidine dehydrogenase (DPYD) is a rate-limiting enzyme catalyzing the response during the first step of the catabolism of 5-FU ([@b4-ijmm-37-02-0319]). Thymidine phosphorylase (TYMP), which is associated with the metabolism of 5-FU, is an enzyme catalyzing the reversible phosphorolysis of 5-FU to 5-fluoro-2′-deoxyuridine. TYMP is identical to platelet-derived endothelial-cell growth factor and is thought to be involved in angiogenesis ([@b5-ijmm-37-02-0319]). Salonga *et al* ([@b6-ijmm-37-02-0319]) and Soong *et al* ([@b7-ijmm-37-02-0319]) reported that the mRNA or protein expression of TYMS, DPYD and TYMP was associated with the antitumor effects of 5-FU. Leucovorin is metabolized *in vivo* into 5,10-methylene-THF, strengthens the ternary complex of FdUMP, TYMS and 5,10-methylene-THF, and strengthens the antitumor effects of 5-FU ([@b8-ijmm-37-02-0319]). Dihydrofolate reductase (DHFR) catalyzes the conversion of dihydrofolate into tetrahydrofolate, which is an important step in the generation of 5,10-methylene-THF ([@b3-ijmm-37-02-0319]). In addition, folate is converted from the monoglutamate to the polyglutamate form by folylpolyglutamate synthase (FPGS) and can therefore be easily maintained within the cells, while the polyglutamate chain is cleaved by gamma-glutamyl hydrolase (GGH) and is converted into the monoglutamate form. It is thought that the catalyzing of opposite reactions by FPGS and GGH in folate metabolism is associated with the adjustment of folate levels in cells, as well as with the augmentation of the effects of 5-FU by leucovorin ([@b9-ijmm-37-02-0319]). Topoisomerase I (TOP1), a target enzyme of irinotecan, destroys the superhelicity observed in DNA during DNA metabolic processes, such as replication and transcription; consequently, TOP1 plays a role in the regulation of DNA topology ([@b10-ijmm-37-02-0319]). The association of excision repair cross-complementing 1 (ERCC1), reportedly associated with the effects of oxaliplatin, is an excision nuclease involved in the nucleotide excision repair of DNA and plays an important role in the repair of platinum-induced DNA adducts ([@b11-ijmm-37-02-0319],[@b12-ijmm-37-02-0319]). Both TOP1 and ERCC1 maintain the normal structure of DNA and are important for DNA functionality. VEGF is a key mediator in angiogenesis, consisting of multiple steps, and its high-level expression is thought to be closely associated with tumor growth and metastasis ([@b13-ijmm-37-02-0319]). EGFR plays an important role in the signaling pathway of epithelial cell growth, and its activation is thought to be closely associated with tumor invasion, metastasis and angiogenesis ([@b14-ijmm-37-02-0319]). Both VEGF and EGFR play important roles in signaling pathways associated with cell growth, such as angiogenesis and proliferation.

It is well known that not only embryological, morphological, physiological and molecular features, but also the prognosis of patients and their sensitivity to chemotherapy depend on whether the primary lesion of colorectal cancer is located on the right or left side ([@b15-ijmm-37-02-0319]--[@b18-ijmm-37-02-0319]). Consequently, the location of the colorectal cancer is thought to be important for deciding individualized treatment for patients with colorectal cancer. However, to the best of our knowledge, to date, there are few studies available on the association between the location of the colorectal cancer and the level of expression of genes related to the effects of chemotherapy for colorectal cancer.

Previously, we performed large-scale population studies investigating TYMS and DPYD activity, as well as protein and mRNA expression in various types of solid tumors and reported basic data regarding the comparisons of assays and the level of expression, according to the carcinoma ([@b19-ijmm-37-02-0319],[@b20-ijmm-37-02-0319]). In this study, primary tumors obtained from 1,129 patients with colorectal cancer who received no chemotherapy were used. After measuring the genes related to standard chemotherapy for colorectal cancer (*TYMS*, *DPYD*, *TYMP*, *DHFR*, *FPGS*, *GGH*, *TOP1*, *ERCC1*, *VEGF* and *EGFR*), a large-scale population analysis was performed for the purpose of determining the association with clinicopathological features, and in particular, the location of the colorectal cancer.

Patients and methods
====================

Patients and samples
--------------------

Between January 2008 and June 2012, we collected samples from primary tumor surgeries conducted on 2,017 patients with colorectal cancer in 39 hospitals across Japan. All the hospitals participated in this study after approval was obtained from the ethical review board of each hospital. Formalin-fixed paraffin-embedded (FFPE) tumor specimens were used for the measurement of mRNA expression. The primary lesions of 1,129 patients with colorectal cancer who did not receive any chemotherapy were analyzed for the mRNA expression of 10 target genes (*TYMS*, *DPYD*, *TYMP*, *DHFR*, *FPGS*, *GGH*, *TOP1*, *ERCC1*, *VEGF* and *EGFR*). Of these, 888 patients were not included in the analysis: 80 patients (4.0%) who received pre-operative chemotherapy; 6 patients (0.3%) who were diagnosed with non-colorectal cancer based on a final pathological examination; 630 patients (31.2%) for whom some of the 10 target genes were not analyzed, at the hospitals\' request; 62 patients (3.1%) for whom none of the 10 target genes were analyzable due to an inadequate number of cancer cells in the FFPE tumor specimens; 110 patients (5.5%) for whom one or more targeted genes were not analyzable due to insufficient tumor volume or considerable variability in the measured values. In addition, not detectable (n.d.) results were included in the analyzed data. The clinicopathological features of the patients were investigated based on the Japanese classification of colorectal cancer: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 7th edition ([@b21-ijmm-37-02-0319]).

Analysis of mRNA expression
---------------------------

The analysis of mRNA expression was performed as previously described ([@b20-ijmm-37-02-0319]). Briefly, the tumor sections (10-*µ*m-thick) were stained with neutral fast red to enable histological visualization during laser-capture microdissection (PALM Robot-microbeam system; P.A.L.M. Microlaser Technologies AG, Munich, Germany), which was performed to ensure that only the tumor cells were collected. RNA was isolated from the FFPE tumor specimens using a novel proprietary procedure (Response Genetics, Los Angeles, CA, USA; United States Patent No. 6,248,535) and cDNA was obtained as previously described ([@b22-ijmm-37-02-0319]). The target cDNA sequences were amplified using quantitative polymerase chain reaction (qPCR) and a fluorescence-based real-time detection method \[ABI PRISM 7900 Sequence Detection System (TaqMan); Applied Biosystems, Foster City, CA, USA\] as previously described ([@b23-ijmm-37-02-0319]--[@b25-ijmm-37-02-0319]). The qPCR reaction mixture consisted of primers, dATP, dCTP, dGTP, dUTP, MgCl~2~ and TaqMan buffer (all reagents were supplied by Applied Biosystems). The qPCR conditions were 50°C for 10 sec and 95°C for 10 min, followed by 42 cycles at 95°C for 15 sec and 60°C for 1 min. The mRNA expression levels were expressed as values relative to those of β-actin (*ACTB*), which was used as the internal reference. If the threshold cycle value for a gene of interest was ≥39.0, the expression for that gene was considered to be not detectable (n.d.), but in the case of *ACTB* it was measured normally.

Statistical analysis
--------------------

mRNA expression was analyzed as a variable which was converted by using the natural logarithm and producing a normal distribution. Pearson\'s pairwise correlation coefficient was used to calculate the correlation of intergenic mRNA expression. For hierarchical cluster analysis of mRNA expression, the data were standardized using the means and standard deviation, while Ward\'s method was used to calculate the distance between clusters. For the equality of means, Welch\'s t-test or one-way analysis of variance (ANOVA) was performed. The analysis of the contingency table was performed using Fisher\'s exact test or χ^2^ test. JMP version 9.0.2 (SAS Institute Japan Co., Ltd., Japan) was used for analysis, and a p-value \<0.05 (two-tailed) was considered to indicate a statistically significant difference. The multiplicity of the test was not considered, as the analysis of this study was exploratory.

Results
=======

Patient characteristics
-----------------------

The clinicopathological features of the 1,129 patients are presented in [Table I](#tI-ijmm-37-02-0319){ref-type="table"}. With regard to tumor location, the percentages obtained were similar for the right- and left-sided colon, and the rectum showed a slightly higher percentage. With regard to the depth of tumor invasion, tumor invasion of mucosa (M), tumor invasion of submucosa (SM) and tumor invasion of muscularis propria (MP) were equivalent to ≤T2 (Tis, T1 and T2) according to the TNM classification, 7th edition, developed by the Union for International Cancer Control (UICC), and accounted for a low percentage of 17.4% of the total. Tumor invasion of subserosa (SS), tumor invasion of serosa (SE), direct tumor invasion of other organs or structure in the intestine with serosa (SI), tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues (A) and direct tumor invasion of other organs or structure in the intestine without serosa (AI) were equivalent to ≥T3 (T3, T4a and T4b) according to the TNM classification and accounted for 79.8%. In addition, non-lymph node metastasis (N0) and lymph node metastases (≥N1) were 41.4 and 56.1%, respectively; stage I/II and stage III/IV disease were 34.0 and 59.6%, respectively, which indicated that the percentage of stage I/II disease tended to be lower.

Intergenic correlation and hierarchical cluster analysis
--------------------------------------------------------

A summary of the results of the mRNA expression of the 10 target genes is presented in [Table II](#tII-ijmm-37-02-0319){ref-type="table"}, and the intergenic correlations obtained are listed in [Table III](#tIII-ijmm-37-02-0319){ref-type="table"}. For the patients whose mRNA expression was not detectable (n.d.), the minimum mRNA expression of that gene was inserted as an alternative. The frequency of n.d. was as follows: *TYMS*, 1 (0.1%); *DPYD*, 35 (3.1%); *TYMP*, 9 (0.8%); *DHFR*, 1 (0.1%); *FPGS*, 2 (0.2%); *GGH*, 5 (0.4%); *TOP1*, 1 (0.1%); *ERCC1*, 2 (0.2%); *VEGF*, 1 (0.1%); and *EGFR*, 2 (0.2%) (data not shown). The frequency of n.d. was the highest in the *DPYD* gene but was in lower than 9 patients (0.8%) for the other genes; therefore, it was considered to have little influence on the results of the analysis.

Additionally, the strongest correlation was noted between *DPYD* and *TYMP* (r= 0.629), followed by *TYMS* and *DHFR* (r=0.596), *GGH* and *TOP1* (r=0.487) and *FPGS* and *ERCC1* (r=0.456). In a hierarchical cluster analysis of mRNA expression, the data were roughly classified into 2 groups: cluster A, in which the mRNA expression of all 10 genes was significantly low, and cluster B, in which the mRNA expression was significantly higher ([Fig. 1](#f1-ijmm-37-02-0319){ref-type="fig"} and [Table IV](#tIV-ijmm-37-02-0319){ref-type="table"}). The associations between the 2 clusters and the clinicopathological features are summarized in [Table V](#tV-ijmm-37-02-0319){ref-type="table"}. A significant difference was noted between the histology, lymphatic invasion, lymph node metastasis and stage. There was a tendency for low-frequency mucinous adenocarcinoma in cluster B and the frequencies of non-lymphatic invasion (ly0), N0 and stage I/II disease were also higher in cluster B.

Association of mRNA expression and clinicopathological features
---------------------------------------------------------------

The association between the mRNA expression of 10 target genes and the clinicopathological features is presented in [Table VI](#tVI-ijmm-37-02-0319){ref-type="table"}. In relation to the location of the tumor, a significant difference was noted in all genes apart from *VEGF* when 4 locations were compared (the right- and left-sided colon, rectosigmoid and rectum), with the exception of the proctos; only 4 patients had a tumor at this location. Specifically, *TYMS* and *DPYD* showed the highest level of expression in the right-sided colon; *GGH* and *EGFR* showed the highest level of expression in the left-sided colon; *DHFR*, *FPGS*, *TOP1* and *ERCC1* showed the highest level of expression in the recto-sigmoid; *TYMP* showed approximately equivalent expression levels in the right-sided colon and rectum, where the expression was higher than in the other locations. On comparing two locations (right- and left-sided colon cancer) in patients with colon cancer only, a significantly high level of expression was noted in right-sided colon cancer for *TYMS* (fold change, 1.22; p=0.0001), *DPYD* (1.27-fold; p=0.001), *TYMP* (1.31-fold; p\<0.0001), and *FPGS* (1.09-fold; p=0.020). By contrast, a significantly high level of expression was observed in left-sided colon cancer for the *GGH* (1.74-fold; p\<0.0001), *TOP1* (1.17-fold; p\<0.0001) and *EGFR* (1.15-fold; p=0.006) genes, and no significant difference was noted for *DHFR* (1.06-fold; p=0.226), *ERCC1* (1.08-fold; p=0.084) and *VEGF* (1.07-fold; p=0.191) (data not shown). For histology, there was a significant difference in 7 genes, excluding *DHFR*, *VEGF* and *EGFR*. For *TYMS*, *DPYD* and *TYMP*, the highest levels of expression were observed in patients with poorly differentiated adenocarcinoma, while the lowest levels of expression were observed in patients with well/moderately differentiated adenocarcinoma. For *FPGS*, *GGH*, *TOP1* and *ERCC1*, the lowest levels of expression were observed in patients with mucinous adenocarcinoma; for *FPGS* and *ERCC1*, the highest level of expression was observed in patients with poorly differentiated adenocarcinoma; and for *GGH* and *TOP1*, the highest level of expression was observed in patients with well/moderately differentiated adenocarcinoma. As regards the depth of tumor invasion, a significantly higher level of expression was found in T1/2 as compared to T3/4 for *TYMS*, *TYMP*, *DHFR*, and *ERCC1*, while higher expression was found in T3/4 for *VEGF* only. For lymph node metastasis, there was a significant difference in *TYMS*, *DHFR* and *ERCC1*; a significantly higher level of expression was found in N0 than N≥1. For stage, there was a significant difference in *TYMS*, *TYMP*, *DHFR* and *ERCC1*, whereas a significantly higher level of expression was found in stage I/II than stage III/IV disease.

Comparison of clinicopathological features in right- or left-sided colon cancer
-------------------------------------------------------------------------------

A comparison of the clinicopathological features between the patients with right- and left-sided colon cancer is presented in [Table VII](#tVII-ijmm-37-02-0319){ref-type="table"}. A significant difference was found with respect to age, histology, lymph node metastasis and stage. The frequencies of elderly individuals, poorly differentiated and mucinous adenocarcinomas, N0 and stage I/II disease tended to be higher in right-sided colon cancer than left-sided colon cancer. The frequency of female patients tended to be higher for right- than left-sided colon cancer although the difference was not significant.

Discussion
==========

In this study, FFPE tumor specimens of primary tumors obtained from 1,129 patients with colorectal cancer were used. We measured mRNA expression levels of 10 genes associated with the effects of standard chemotherapy for colorectal cancer (*TYMS*, *DPYD*, *TYMP*, *DHFR*, *FPGS*, *GGH*, *TOP1*, *ERCC1*, *VEGF* and *EGFR*), and determined their association with clinicopathological features, in particular, the location of colorectal cancer.

From the results of mRNA expression analysis of the 10 genes included in this study, the strongest correlation was noted between *DPYD* and *TYMP*. Several studies have reported a similar correlation between expression levels in colorectal cancer ([@b26-ijmm-37-02-0319]--[@b33-ijmm-37-02-0319]). *DPYD* and *TYMP* encode enzymes related to the metabolism of 5-FU, and it seems likely that the expression levels of these genes in colorectal cancer tissues are co-regulated. In addition, the results from this study indicate a weaker correlation between *TYMS* and *DHFR* than that between *DPYD* and *TYMP*. Uetake *et al* also reported a similar correlation in stage III colon cancer ([@b33-ijmm-37-02-0319]). Considering that DHFR plays an important role in the generation of 5,10-methylene-THF as a co-factor of the TYMS response, it is plausible that the level of gene expression of both enzymes is correlated.

It has previously been reported that colorectal cancer, particularly colon cancer, exhibits embryologic, morphologic, physiologic and molecular differences between the right and left sides, which leads to differences in the prognosis of patients and their sensitivity to chemotherapy ([@b15-ijmm-37-02-0319]--[@b18-ijmm-37-02-0319]). In relation to the clinicopathological features, in these studies, it has been posited that the numbers of elderly individuals, women, mucinous adenocarcinoma, high grade (poorly differentiated/undifferentiated) and negative lymph node metastasis is higher in right- than left-sided colon cancer. In our study, similar, reproducible results were noted. As regards the molecular features, a microsatellite instability phenotype (MSI^+^) and CpG island methylator phenotype (CIMP^+^) are common in right-sided colon cancer, whereas chromosomal instability is common in left-sided colon cancer ([@b15-ijmm-37-02-0319]--[@b18-ijmm-37-02-0319]). Kawakami *et al* ([@b34-ijmm-37-02-0319]) analyzed the association between the CIMP^+^ status and the expression level of gene-related folate and nucleotide metabolism in the primary tumors of 114 patients from Australia with colorectal cancer. They reported that the low-level expression of *GGH* and high-level expression of *TYMP* were very strongly associated with CIMP^+^ and CIMP^+^-related clinicopathological and molecular features. They also reported that a significantly higher level of *TYMP* expression and a significantly lower level of *GGH* expression were found in right- as compared to left-sided colorectal cancer ([@b34-ijmm-37-02-0319]). Moreover, they pointed out the possibility that low-level *GGH* expression may lead to the maintenance of folate in the polyglutamate form in the cells, which is associated with DNA hypermethylation, and that 5-FU plus leucovorin therapy may then be more effective ([@b34-ijmm-37-02-0319]). In a study of 76 Japanese patients with stage II/III colorectal cancer, Sadahiro *et al* reported that a significantly high level of *TYMP* expression was found in cases of right rather than left-sided colorectal cancer and that preoperative uracil-tegafur (UFT) plus leucovorin therapy resulted in a significantly strong histological response ([@b35-ijmm-37-02-0319]). In the present study, in relation to right-sided colon cancer, we noted a significantly higher level of *TYMP* expression and a lower level *GGH* expression than in left-sided colon cancer. Considering these results, it may be worthwhile to determine the physiological significance of *TYMP* and *GGH* expression in patients with colorectal cancer in the future, in order to examine the hypothesis that 5-FU-based chemotherapy combined with leucovorin may be more effective in cases of right-sided colon cancer.

Ricciardiello *et al* reported that *TYMS* protein expression, as assessed by immunohistochemistry (IHC), did not differ significantly between right- and left-sided colorectal cancer, but a significantly high level of expression in MSI^+^ colorectal cancer was noted ([@b36-ijmm-37-02-0319]). Jensen *et al* also reported that the protein expression of TYMS (studied by IHC) was significantly high in MSI^+^ colorectal cancer ([@b37-ijmm-37-02-0319]). On the other hand, Sinicrope *et al* reported that there was no correlation between the MSI^+^ status and TYMS protein expression (as measured by IHC) ([@b38-ijmm-37-02-0319]). Thus, the association between TYMS protein expression and the MSI^+^ status remains controversial. In our study, as regards *TYMS*, its mRNA expression was found to be higher in right-sided colon cancer in which MSI^+^ was common, than in left-sided colon cancer. The analysis of the clinicopathological features of all the patients with colorectal cancer in this study revealed a high level of *TYMS* expression in the elderly, those with poorly differentiated adenocarcinoma and N0, which are common in right-sided colon cancer. However, as regards the association between *TYMS* expression and the location of colorectal cancer, further studies, which will include the association of *TYMS* with molecular features, such as the MSI^+^ status, are warranted in the future.

Recently, Missiaglia *et al* performed gene expression analysis of a colon cancer dataset on 914 patients who were registered in The Cancer Genome Atlas (TCGA) collection and Pan European Trial Adjuvant Colon Cancer (PETACC3) adjuvant chemotherapy trial. According to their study, the expression of *EGFR* and human epidermal growth factor receptor 2 (*HER2*) was advanced in left- rather than right- sided colon cancer, which activated EGF signaling, and the usefulness of anti-*EGFR* agents was suggested ([@b39-ijmm-37-02-0319]). Similarly, the results of our study demonstrated that a significantly higher level of *EGFR* expression was noted in left- rather than right-sided colon cancer. Hence, it is necessary to perform research on individualized treatment which combines the location of colorectal cancer and *EGFR* expression levels with the mutation status of *KRAS* and *BRAF*, as well as *EGFR* inhibitors.

Loupakis *et al* analyzed three independent cohorts in order to examine the association between the primary tumor of metastatic colorectal cancer and the efficacy of first-line chemotherapy. They reported that patients with primary tumors on the left side of the colon achieved significantly superior overall survival than those with primary tumors on the right side ([@b40-ijmm-37-02-0319]). They also analyzed gene expression in an exploratory manner using the archival series of 181 independent primary tumor samples. They inferred that the mRNA expression of *ERCC1* was significantly higher in right- rather than left-sided colorectal cancer, although the mRNA expression level of *VEGF* ligands *A*, *B* and *C*, as well as *VEGF receptors 1* and *2* showed no difference between right- and left-sided colorectal cancer. This is, perhaps, one of the factors involved in chemo-resistance in patients with right-sided colorectal cancer ([@b40-ijmm-37-02-0319]). In our study, although *VEGF* exhibited few differences in the level of expression according to the location of the tumor and the expression of *ERCC1* was the lowest in the patients with left-sided colon cancer, the level of expression for *ERCC1* was the highest in the rectosigmoid. Additionally, for *ERCC1*, there was no significant difference in the comparison between right- and left-sided colon cancer. Further research on the differences in sensitivity to oxaliplatin between patients with right- and left-sided colorectal cancer and the association with *ERCC1* expression is warranted.

In our analysis of the association between gene expression and five factors related to the extent of cancer, namely lymphatic invasion, vein invasion, depth of tumor invasion, lymph node metastasis and stage, a significant difference was noted in all the five factors for *TYMS*; whereas *DPYD*, *TYMP*, *DHFR*, *FPGS*, *ERCC1* and *VEGF* showed a significant difference in 1--4 factors. Of these, with the exception that the *VEGF* gene showed a significantly higher level of expression in T3/4 than T1/2, high-level expression was found in the group at a less-advanced stage rather than the group in the more advanced stages of cancer. This tendency is consistent with the results of the hierarchical cluster analysis. However, a comparison of patient characteristics was made between the 1,129 Japanese patients with colorectal cancer in our study and the data from 30,002 patients who were registered with the Japanese Society for Cancer of the Colon and Rectum between 1993 and 1997 ([@b41-ijmm-37-02-0319]), as well as the data from 621 patients who were registered in a single institution in Japan between 1992 and 2002 ([@b42-ijmm-37-02-0319]). This comparison revealed that, although age, gender, tumor location and histology had generally similar distributions, the percentages of T1/2, N0 and stage I/II were clearly low, and as a whole, the stage of cancer tended to be more advanced in our study. Consequently, it is likely necessary to consider the data on the association between gene expression levels in this study and the clinicopathological features associated with the progress of cancer with caution.

In this large-scale population study, we clarified the association between the mRNA expression of genes associated with the effects of standard chemotherapy for colorectal cancer and clinicopathological features, particularly the location of the colorectal cancer. It is hoped that the results of this study will become useful reference data for conducting research on individualized chemotherapy for colorectal cancer that takes into consideration the location of colorectal cancer.

The authors wish to thank all of the patients who participated in this study, and the clinicians at the hospitals named in the [Appendix](#app1-ijmm-37-02-0319){ref-type="app"}, who collaborated with us in measuring gene expression in the colorectal cancer specimens. In addition, we would like to thank Editage ([www.editage.jp](http://www.editage.jp)) for English language editing.

Collaborating hospitals: Chiba University Hospital, Fujita Health University Hospital, Gifu University Hospital, Hachioji Digestive Disease Hospital, Handa City Hospital, Himeji Medical Center, Hyogo Prefectural Kakogawa Medical Center, JCHO Kobe Central Hospital, Kanto Rosai Hospital, Keio University Hospital, Kinki University Hospital, Kitano Hospital, Kobe City Medical Center General Hospital, Kobe City Medical Center West Hospital, Kohsei Chuo General Hospital, Nagoya University Hospital, National Center for Global Health and Medicine Center Hospital, Nihon University Itabashi Hospital, Niitsu Medical Center Hospital, Omori Red Cross Hospital, Osaka Rosai Hospital, Osaka University Hospital, Saitama Medical Center, Sakai City Hospital, Sendai Red Cross Hospital, Showa University Fujigaoka Hospital, Showa University Hospital, The Jikei University Hospital, Tohoku Rosai Hospital, Tohoku University Hospital, Toho University Omori Medical Center, Tokushima Red Cross Hospital, Tokyo Medical University Hachioji Medical Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo Metropolitan Tama Medical Center, Totsuka Kyoritsu Second Hospital, Toyohashi Municipal Hospital, University of Yamanashi Hospital, Yamaguchi University Hospital.

![Hierarchical clustering of 10 gene mRNA expression.](IJMM-37-02-0319-g00){#f1-ijmm-37-02-0319}

###### 

Clinicopathological features of the 1,129 patients.

  Clinicopathological features                                  No. of patients   \%
  ------------------------------------------------------------- ----------------- ------
  Age (mean, 66 years; median, 67 years; range, 24--94 years)                     
   \<67                                                         525               46.5
   ≥67                                                          558               49.4
   No available data                                            46                4.1
  Gender                                                                          
   Male                                                         662               58.6
   Female                                                       459               40.7
   No available data                                            8                 0.7
  Tumor location                                                                  
   Right-sided colon (C, A, T)                                  324               28.7
   Left-sided colon (D, S)                                      317               28.1
   Rectosigmoid                                                 117               10.4
   Rectum                                                       358               31.7
   Proctos                                                      4                 0.4
   No available data                                            9                 0.8
  Histology                                                                       
   Well/moderately differentiated                               1004              88.9
   Poorly differentiated                                        35                3.1
   Mucinos                                                      32                2.8
   Others                                                       16                1.4
   No available data                                            42                3.7
  Lymphatic invasion                                                              
   ly0                                                          292               25.9
   ly1, ly2, ly3                                                746               66.1
   No available data                                            91                8.1
  Venous invasion                                                                 
   v0                                                           364               32.2
   v1, v2, v3                                                   670               59.3
   No available data                                            95                8.4
  Depth of tumor invasion                                                         
   M, SM, MP                                                    197               17.4
   SS, SE, SI, A, AI                                            901               79.8
   No available data                                            31                2.7
  Lymph node metastasis                                                           
   N0                                                           467               41.4
   N1, N2, N3                                                   633               56.1
   No available data                                            29                2.6
  Stage                                                                           
   0                                                            9                 0.8
   I                                                            106               9.4
   II                                                           278               24.6
   III                                                          482               42.7
   IV                                                           191               16.9
   No available data                                            63                5.6

Based on the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (Japanese Society for Cancer of the Colon and Rectum, 7th edition) ([@b21-ijmm-37-02-0319]). Tumor location: C, cecum; A, ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon. Depth of tumor invasion: M, tumor invasion of mucosa; SM, tumor invasion of submucosa; MP, tumor invasion of muscularis propria; SS, tumor invasion of subserosa; SE, tumor invasion of serosa, SI, direct tumor invasion of other organs or structure in the intestine with serosa; A, tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues; AI, direct tumor invasion of other organs or structure in the intestine without serosa.

###### 

Summary of the mRNA expression levels of the 10 genes analyzed in this study in the 1,129 patients.

  Gene      Gene expression/β-actin values   Log-transformed values                    
  --------- -------------------------------- ------------------------ -------- ------- ------
  *TYMS*    3.86                             0.40                     64.20    1.34    0.66
  *DPYD*    0.28                             0.03                     4.61     −1.30   0.85
  *TYMP*    2.72                             0.22                     45.30    1.02    0.79
  *DHFR*    4.33                             0.40                     27.46    1.43    0.63
  *FPGS*    0.59                             0.15                     4.49     −0.53   0.49
  *GGH*     12.71                            0.26                     166.47   2.45    1.09
  *TOP1*    2.79                             0.41                     107.07   1.02    0.52
  *ERCC1*   1.67                             0.27                     18.06    0.52    0.55
  *VEGF*    7.39                             0.93                     73.19    1.99    0.65
  *EGFR*    1.35                             0.11                     55.07    0.29    0.61

###### 

Correlations of the mRNA expression of the 10 log-transformed genes.

  Gene      *TYMS*   *DPYD*   *TYMP*   *DHFR*   *FPGS*   *GGH*   *TOP1*   *ERCC1*   *VEGF*   *EGFR*
  --------- -------- -------- -------- -------- -------- ------- -------- --------- -------- --------
  *TYMS*    1                          0.596                              0.427              
  *DPYD*             1        0.629                                                          
  *TYMP*             0.629    1                                                              
  *DHFR*    0.596                      1                 0.438   0.387    0.373              
  *FPGS*                                        1                         0.456              
  *GGH*                                0.438             1       0.487                       
  *TOP1*                               0.387             0.487   1                  0.341    
  *ERCC1*   0.427                      0.373    0.456                     1                  
  *VEGF*                                                         0.341              1        
  *EGFR*                                                                                     1

Only Pearson\'s correlations \>0.3 are shown (p\<0.0001).

###### 

Log-transformed mRNA expression levels of two clusters.

  Gene      Gene expression/β-actin values   p-value      
  --------- -------------------------------- ------------ ----------
  *TYMS*    1.04±0.61                        1.61±0.60    \<0.0001
  *DPYD*    −1.62±0.88                       −1.00±0.72   \<0.0001
  *TYMP*    0.82±0.81                        1.20±0.72    \<0.0001
  *DHFR*    1.08±0.56                        1.75±0.51    \<0.0001
  *FPGS*    −0.71±0.46                       −0.37±0.46   \<0.0001
  *GGH*     1.97±1.11                        2.90±0.86    \<0.0001
  *TOP1*    0.84±0.48                        1.19±0.49    \<0.0001
  *ERCC1*   0.24±0.44                        0.78±0.52    \<0.0001
  *VEGF*    1.69±0.59                        2.26±0.59    \<0.0001
  *EGFR*    0.11±0.54                        0.45±0.64    \<0.0001

p-values were calculated by Welch\'s t-test.

###### 

Comparison of clinicopathological features in two clusters of gene expression.

  Clinicopathological features      No. of patients   p-value   
  --------------------------------- ----------------- --------- -------
  Age (years)                                                   
   \<67                             252               273       0.394
   ≥67                              253               305       
  Gender                                                        
   Male                             312               350       0.761
   Female                           221               238       
  Tumor location                                                
   Right-sided colon                150               174       0.305
   Left-sided colon                 156               161       
   Rectosigmoid                     47                70        
   Rectum                           177               181       
  Histology                                                     
   Well/moderately differentiated   479               525       0.008
   Poorly differentiated            15                20        
   Mucinous                         24                8         
  Lymphatic invasion                                            
   ly0                              129               163       0.039
   ly1, ly2, ly3                    383               363       
  Venous invasion                                               
   v0                               171               193       0.241
   v1, v2, v3                       341               329       
  Depth of tumor invasion                                       
   T1, T2                           102               95        0.238
   T3, T4                           424               477       
  Lymph node metastasis                                         
   N0                               202               265       0.006
   N1, N2, N3                       327               306       
  Stage                                                         
   I, II                            166               218       0.013
   III, IV                          345               328       

p-values were calculated by Fisher\'s exact test or χ^2^ test.

###### 

Associations between log-transformed mRNA expression levels and clinicopathological features.

  Clinicopathological features   Log-transformed mRNA expression levels (means ± SD)                                                                                                      
  ------------------------------ ----------------------------------------------------- ------------ ----------- ----------- ------------ ----------- ----------- ------------ ----------- -----------
  Age (years)                                                                                                                                                                             
   \<67                          1.30±0.63                                             −1.33±0.84   1.03±0.75   1.42±0.63   −0.55±0.49   2.52±1.04   1.04±0.51   0.51±0.55    1.96±0.64   0.31±0.59
   ≥67                           1.39±0.67                                             −1.24±0.87   1.01±0.82   1.48±0.60   −0.50±0.49   2.43±1.13   1.02±0.52   0.57±0.55    2.01±0.68   0.26±0.62
   p-value                       0.024                                                 0.084        0.687       0.161       0.122        0.174       0.715       0.069        0.178       0.195
  Gender                                                                                                                                                                                  
   Male                          1.34±0.65                                             −1.25±0.82   1.03±0.77   1.43±0.63   −0.52±0.48   2.53±1.07   1.06±0.53   0.51±0.54    2.02±0.65   0.30±0.61
   Female                        1.34±0.68                                             −1.36±0.90   1.00±0.82   1.44±0.63   −0.53±0.51   2.36±1.12   0.97±0.49   0.55±0.57    1.94±0.65   0.27±0.62
   p-value                       0.973                                                 0.045        0.519       0.741       0.715        0.014       0.004       0.292        0.053       0.505
  Tumor location                                                                                                                                                                          
   Right-sided colon             1.45±0.66                                             −1.20±0.92   1.11±0.87   1.48±0.63   −0.50±0.47   2.15±1.05   0.91±0.52   0.54±0.58    1.95±0.67   0.22±0.57
   Left-sided colon              1.25±0.67                                             −1.44±0.78   0.84±0.73   1.42±0.60   −0.59±0.49   2.71±0.89   1.07±0.49   0.47±0.52    2.02±0.67   0.36±0.71
   Rectosigmoid                  1.43±0.60                                             −1.25±0.86   0.99±0.73   1.54±0.52   −0.45±0.48   2.65±1.08   1.11±0.43   0.66±0.58    1.98±0.55   0.34±0.64
   Rectum                        1.29±0.66                                             −1.26±0.83   1.11±0.75   1.35±0.67   −0.53±0.51   2.46±1.12   1.05±0.53   0.52±0.55    1.99±0.65   0.27±0.55
   p-value                       0.0002                                                0.004        \<0.0001    0.014       0.028        \<0.0001    \<0.0001    0.016        0.610       0.022
  Histology                                                                                                                                                                               
   Well/moderately               1.31±0.65                                             −1.35±0.81   0.98±0.76   1.42±0.62   −0.54±0.49   2.51±1.05   1.03±0.52   0.52±0.55    1.99±0.65   0.30±0.59
   differentiated                                                                                                                                                                         
   Poorly differentiated         1.82±0.67                                             −0.52±1.18   1.80±1.03   1.47±0.82   −0.38±0.44   1.84±1.28   1.02±0.38   0.64±0.63    1.85±0.79   0.08±1.12
   Mucinous                      1.48±0.62                                             −0.70±0.96   1.22±0.65   1.26±0.70   −0.69±0.53   1.19±1.13   0.76±0.50   0.27±0.50    1.88±0.65   0.24±0.52
   p-value                       \<0.0001                                              \<0.0001     \<0.0001    0.307       0.035        \<0.0001    0.016       0.017        0.309       0.113
  Lymphatic invasion                                                                                                                                                                      
   ly0                           1.42±0.66                                             −1.26±0.90   1.16±0.75   1.45±0.66   −0.52±0.51   2.46±1.15   1.03±0.52   0.56±0.61    1.98±0.62   0.31±0.59
   ly1, ly2, ly3                 1.29±0.66                                             −1.32±0.84   0.94±0.79   1.39±0.62   −0.53±0.49   2.43±1.08   1.01±0.52   0.49±0.54    1.95±0.66   0.28±0.63
   p-value                       0.006                                                 0.326        \<0.0001    0.204       0.736        0.751       0.651       0.086        0.447       0.595
  Venous invasion                                                                                                                                                                         
   v0                            1.42±0.67                                             −1.21±0.89   1.08±0.79   1.45±0.63   −0.49±0.50   2.37±1.09   1.02±0.51   0.54± 0.59   1.94±0.63   0.28±0.61
   v1, v2, v3                    1.28±0.66                                             −1.36±0.83   0.96±0.78   1.38±0.64   −0.50±0.49   2.47±1.10   1.02±0.53   0.49± 0.54   1.96±0.65   0.30±0.63
   p-value                       0.001                                                 0.012        0.026       0.117       0.048        0.179       0.876       0.218        0.608       0.668
  Depth of tumor invasion                                                                                                                                                                 
   T1, T2                        1.46±0.61                                             −1.25±0.95   1.13±0.79   1.54±0.58   −0.53±0.50   2.47±1.03   1.07±0.48   0.60±0.57    1.79±0.57   0.30±0.52
   T3, T4                        1.32±0.67                                             −1.32±0.82   0.98±0.78   1.40±0.64   −0.52±0.49   2.44±1.10   1.01±0.52   0.51±0.55    2.03±0.66   0.28±0.64
   p-value                       0.003                                                 0.381        0.015       0.004       0.924        0.722       0.118       0.041        \<0.0001    0.700
  Lymph node metastasis                                                                                                                                                                   
   N0                            1.43±0.68                                             −1.30±0.88   1.05±0.80   1.49±0.62   −0.51±0.49   2.50±1.09   1.04±0.53   0.59±0.58    1.97±0.67   0.26±0.56
   N1, N2, N3                    1.28±0.64                                             −1.30±0.82   0.99±0.77   1.38±0.63   −0.54±0.49   2.41±1.09   1.00±0.51   0.48±0.53    2.00±0.64   0.31±0.65
   p-value                       0.0002                                                0.889        0.193       0.004       0.486        0.186       0.214       0.001        0.366       0.195
  Stage                                                                                                                                                                                   
   I, II                         1.43±0.67                                             −1.29±0.88   1.10±0.79   1.48±0.62   −0.51±0.50   2.48±1.09   1.03±0.53   0.58±0.58    1.95±0.66   0.27±0.56
   III, IV                       1.29±0.65                                             −1.32±0.83   0.95±0.79   1.39±0.63   −0.53±0.49   2.42±1.09   1.02±0.51   0.48±0.53    1.99±0.65   0.29±0.65
   p-value                       0.002                                                 0.706        0.004       0.019       0.575        0.370       0.610       0.004        0.302       0.556

p-values were calculated by Welch\'s t-test or one-way ANOVA.

###### 

Comparison of clinicopathological features with the location of the colorectal cancer.

  Clinicopathological features      No. of patients   p-value   
  --------------------------------- ----------------- --------- ----------
  Age (years)                                                   
   \<67                             105               159       \<0.0001
   ≥67                              205               148       
  Gender                                                        
   Male                             166               183       0.175
   Female                           151               133       
  Histology                                                     
   Well/moderately differentiated   279               291       0.001
   Poorly differentiated            16                9         
   Mucinous                         17                2         
  Lymphatic invasion                                            
   ly0                              88                73        0.197
   ly1, ly2, ly3                    211               224       
  Venous invasion                                               
   v0                               115               96        0.145
   v1, v2, v3                       184               199       
  Depth of tumor invasion                                       
   T1, T2                           40                32        0.382
   T3, T4                           278               282       
  Lymph node metastasis                                         
   N0                               146               115       0.029
   N1, N2, N3                       173               196       
  Stage                                                         
   I, II                            118               93        0.041
   III, IV                          186               210       

p-values were calculated by Fisher\'s exact test or χ^2^ test.
